Xtram

Quick links to important sections

Xtram

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xtram

What is Xtram? Overview

Property Description
Active ingredient Tramadol hydrochloride
Form Tablet, Capsule, Solution, Injection
Pharmacological class Central analgesic, Opioid receptor agonist
Common use Management of moderate to moderately severe pain
Origin Synthetic

What is Xtram and Its Pharmacological Classification?

Xtram is a prescription-only medication whose active ingredient is Tramadol hydrochloride, clinically recognized as a highly effective central analgesic. Tramadol is categorized as an opioid agonist indicated for the management of pain. This established categorization confirms the drug’s primary role in systematically reducing pain signals within the central nervous system. It is a synthetic opioid, meaning it is chemically engineered, a key feature that provides a different structure and pharmacological profile compared to traditional naturally derived narcotics. Its fundamental role is to provide strong analgesic efficacy for general pain management in adult patients.

Composition and Available Pharmaceutical Preparations

The core chemical makeup of Xtram confirms it as a single active ingredient product, containing only Tramadol hydrochloride alongside necessary inert pharmaceutical excipients or aqueous vehicles. The medicine is made available in several pharmaceutical preparations, enabling flexible administration. These dosage forms include standard oral tablets and capsules, an oral solution for liquid delivery, and preparations for injection (parenteral administration). Tramadol exists in diverse forms, including immediate-release and extended-release forms. The availability of the specialized extended-release form is a differentiating factor, allowing for consistent, sustained relief, which is vital for managing chronic pain in situations where continuous coverage is required.

General Purpose and Action Principle

The fundamental purpose of Xtram is the effective mitigation of moderate to moderately severe pain. The drug achieves its goal through a unique, dual or biphasic mechanism of action that influences the body's pain pathways at multiple points. This involves activating certain opioid receptors while simultaneously modulating key neurochemicals like serotonin and norepinephrine, ensuring a comprehensive effect on the transmission of pain signals.

What side effects are possible with Xtram?

Possible Side Effects and Safety Information for Xtram

The safety profile for Xtram (Tramadol hydrochloride) is formally established by regulatory authorities, with adverse reactions classified by frequency and affected physiological system. The most commonly reported adverse effects primarily involve the nervous and gastrointestinal systems.


Frequency-Classified Adverse Reactions

Adverse reactions are classified according to incidence based on clinical data:

  • Very Common (1/10): Nausea and Dizziness.
  • Common (1/100 to < 1/10): Vomiting, Constipation, Dry mouth, Somnolence, Headache, and Sweating (Hyperhidrosis).
  • Uncommon (1/1,000 to < 1/100): Includes gastrointestinal irritation (e.g., abdominal pain) and cardiovascular effects, such as Orthostatic hypotension.

Clinically Significant Adverse Reactions

Regulatory documents highlight specific serious adverse reactions. These include life-threatening Respiratory Depression, which is a critical risk associated with opioid agonists. The possibility of Seizures (Convulsions) is documented, particularly at higher doses or in combination with other seizure-risk lowering medications. Furthermore, the risk of developing Serotonin Syndrome and the potential for Opioid Dependence and withdrawal symptoms are officially noted safety concerns.


Population-Specific Safety Considerations

The medicine's elimination may be altered in specific populations. Safety statements address the use in Older Adults (aged 75 years and older) and patients with impaired Hepatic or Renal function, where altered clearance can increase drug exposure. Additionally, adverse effects like nausea and dizziness are often noted as more frequent at the start of treatment or during initial dose escalation, gradually subsiding with continued use.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on official government regulatory documents regarding Xtram (tramadol) overdose.

Overdose Manifestations and Risks

An overdose of Xtram can lead to severe and potentially fatal outcomes. The most serious documented manifestations involve the Central Nervous System (CNS) and the Respiratory System.

Documented Symptoms

  • Life-threatening respiratory depression (slow, shallow breathing)
  • Profound sedation leading to coma
  • Seizures or convulsions
  • Miosis (pinpoint pupils)
  • Cardiovascular collapse

Specific Risks

Accidental ingestion, particularly by children, is officially documented as a risk for fatal overdose. Patients classified as ultra-rapid metabolizers or those who are elderly are at increased risk for life-threatening respiratory depression.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose.

Seek emergency medical help or call 911 immediately if any signs of overdose are observed, especially slow or shallow breathing, or if the person is unable to be woken up.

Management: Official guidance specifies the administration of naloxone (an opioid reversal agent) to manage respiratory depression, along with establishing a patent airway and providing supportive ventilation.

Therapeutic Uses of Xtram

Quick Facts: Xtram Therapeutic Domains

  • Relieves: Minor skin irritations and rashes (e.g., due to poison ivy or insect bites)
  • Addresses: Temporary itching and pain associated with minor external injuries

Xtram is authorized for the management of temporary pain and itching associated with certain minor skin conditions. It may offer symptomatic relief for discomfort resulting from minor burns, scrapes, minor cuts, and insect bites. The medication is also utilized to help relieve irritation and itching associated with rashes, such as those caused by exposure to poison ivy, poison oak, and poison sumac. Xtram is intended for external use only on the affected area to provide temporary, localized relief of symptoms.

Regulatory References

  1. NIH DailyMed labeling guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Xtram?

The population eligibility for Xtram (Tramadol) is strictly defined by government regulatory documents, establishing clear limitations and absolute contraindications.


Contraindicated Populations

Xtram is absolutely contraindicated for several high-risk groups:

  • Children younger than 12 years of age.
  • Pediatric patients under 18 following tonsillectomy and/or adenoidectomy.
  • Individuals with known or suspected gastrointestinal obstruction (e.g., paralytic ileus).
  • Patients with significant respiratory depression or acute, severe bronchial asthma.
  • Patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing them.

Restricted and Special-Consideration Groups

Population Group Eligibility Status Official Restriction Basis
Pregnancy and Lactation Not Recommended Risk of Neonatal Opioid Withdrawal Syndrome (NOWS) or adverse infant effects.
Severe Organ Impairment Not Recommended Severe hepatic or severe renal impairment (especially for extended-release formulations).
Older Adults (over 75) Conditional Use Requires special consideration due to delayed drug elimination.

The drug is generally approved for use in adults 18 years and older.

What should I know about interactions with other medicines?

Xtram Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Xtram (Tramadol hydrochloride) around specific contraindications and required cautions.


Formal Contraindicated Combinations

The co-administration of Xtram with certain substances is strictly prohibited due to the risk of severe adverse reactions:

  • Monoamine Oxidase Inhibitors (MAOIs): Use is contraindicated, including within 14 days of discontinuing an MAOI, due to the documented risk of Serotonin Syndrome and seizures.
  • Alcohol: The drug is contraindicated in acute intoxication with alcohol or other CNS depressants.
  • Other Tramadol Products: Concomitant use is prohibited to prevent overexposure.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interactions often involve the drug's metabolism or additive effects on the central nervous system (CNS).

Interaction Type Interacting Categories (Official Documentation)
Metabolic CYP2D6/CYP3A4 Inhibitors and Inducers: These substances can alter the plasma levels of Xtram and its active metabolite, potentially affecting drug exposure. Examples include Carbamazepine (Inducer) and Fluoxetine (Inhibitor).
Pharmacodynamic Serotonergic Drugs: Co-administration with SSRIs, SNRIs, and Triptans increases the documented risk of Serotonin Syndrome. CNS Depressants: Substances like Benzodiazepines increase the risk of profound sedation and respiratory depression.

Population and Substance Constraints

The regulatory label includes specific population restrictions, notably the CYP2D6 Ultra-Rapid Metabolizer status, where use is restricted due to the increased risk of life-threatening respiratory depression. The official documents also note that St. John's Wort may interfere with Xtram’s metabolism as a CYP3A4 inducer.

Mechanism of Action

Tramadol's physiological action involves a biphasic mechanism that modulates signaling pathways within the central nervous system. It primarily affects processes within the brain and spinal cord by engaging two distinct systems simultaneously.

Dual Modulation of Opioid Receptors and Neurotransmitters

The mechanism involves two complementary actions. First, its M1 metabolite acts as an agonist at the mu-opioid receptor (mu-OR), initiating a molecular cascade that directly reduces the excitability of nerve cells. Second, the parent drug inhibits the reuptake of the monoamine neurotransmitters Serotonin (5-HT) and Norepinephrine (NE). This dual activity provides a basis for targeted interference with signaling.

Enhancement of Descending Inhibitory Control

By increasing the concentration of Serotonin and Norepinephrine, the mechanism enhances signaling within the descending inhibitory pathway. This process enhances the inhibitory control exerted on the transmission of afferent signals at the spinal level. This system-level change results in a state of central nervous system modulation.

Constraint by Metabolic Pathway

The expression of the mu-opioid mechanism is reliant on the individual's metabolic capacity, specifically the activity of the CYP2D6 enzyme. If this conversion to the M1 metabolite is constrained by genetic variance (Poor Metabolizers), the opioid component of the dual mechanism is significantly reduced, limiting the extent of central modulation.

Dosage and Administration Information

How to Use Xtram

Xtram (Tramadol hydrochloride) administration is established for its use as a central analgesic. The medication is available for the oral route (as immediate-release or extended-release tablets/capsules, and as a solution) and for parenteral administration via intravenous (IV) or intramuscular (IM) injection.

Dosing schedules are defined for oral formulations. Immediate-release (IR) forms are typically administered every four to six hours as required for pain relief, with the total daily dose not exceeding 400 mg. Conversely, extended-release (ER) forms are intended for sustained relief and are administered once daily; the maximum daily dose is generally limited to 300 mg.

Oral formulations can be taken with or without food; however, consistency is required for the extended-release form. A critical administration instruction is that extended-release tablets must be swallowed whole and must not be broken, crushed, or dissolved to prevent the immediate, uncontrolled release of the full dose. For the oral solution, a specialized dosing device must be used for accurate measurement.

Specific population adjustments are applied to the administration parameters. Use is contraindicated in children under 12 years of age. For individuals over 75 years of age or those with severe renal or hepatic impairment, the dosing interval for IR forms must be extended (e.g., to every 12 hours), and the maximum daily dose is lowered. For all uses, treatment should employ the shortest duration consistent with the clinical goal, and discontinuation, particularly after long-term use, requires a gradual tapering process.

Recent Clinical Evidence

Recent Clinical Evidence for Xtram

Clinical research on compounds related to 'Xtram' or similar investigational agents often focuses on diverse therapeutic areas, including metabolic disorders and cardiovascular interventions. The studies aim to establish the profile of these agents regarding their potential effects on various health indicators, as well as to document their tolerability over time.

Key areas of investigation for related drug classes typically involve Phase III randomized, controlled trials, which compare the investigational agent against a placebo or an active comparator treatment. Trials are designed with specific endpoints to measure potential changes in health status.

Examples of Investigational Study Design

Studies for agents sharing the nomenclature or target area of 'Xtram' have frequently adopted the following methodologies to assess outcomes:

  • Study Type: Randomized, double-blind, or open-label comparator trials.
  • Primary Endpoints: Common primary measures include changes from baseline in specific biomarkers (e.g., HbA1c levels, LDL-C), changes in body weight, or measurements of physical function (e.g., freedom from adverse vascular events).

Clinical trials are structured to collect data on both the intended effects and any observed side effects. For instance, in an open-label, multi-center trial (the XTREME Study) comparing an agent (Xuezhikang) similar to a known compound within the cardiovascular space (atorvastatin), the primary focus was on the change in HbA1c levels over a 24-week treatment period in patients with dyslipidemia and prediabetes.

Detailed study results, including the statistical significance of primary and secondary endpoints, are typically published in medical literature or made available on clinical trial registries to provide a comprehensive view of the investigational drug's profile for healthcare professionals.

Key Studies & References

  1. Clinical Research Glossary - The Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard
  2. A Narrative Review of the Strengths and Limitations of Real-World Evidence in Comparison to Randomized Clinical Trials: What Are the Opportunities in Thoracic Oncology for Real-World Evidence to Shine?

Frequently Asked Questions (FAQ)

Common questions about Xtram (FAQ)


Q: How long does it usually take to notice any effects from Xtram?

According to the official product information for the immediate-release oral form, the medicine typically begins working within one hour. The maximum effects of the drug are usually observed within two to three hours following administration.

Q: What happens if I stop taking Xtram suddenly?

Official guidelines recommend a gradual reduction of the dose, or tapering, when discontinuing the medicine, especially after long-term use. Abrupt discontinuation is noted as a risk factor for withdrawal symptoms in regulatory documents.

Q: Is it true that Xtram can cause issues with sleep?

Yes, official regulatory documents list somnolence (drowsiness) as a common adverse reaction. Other sleep-related issues, such as insomnia or abnormal dreams, are sometimes classified as less common or rare adverse reactions in official safety documents.

Q: Does Xtram interact with common over-the-counter pain relievers?

Regulatory documents focus on interactions with broad drug categories, but no formal contraindication is typically listed for common pain relievers like acetaminophen. Official documents advise caution regarding the co-administration of Xtram with other medicines that may cause sedation or central nervous system (CNS) depression.

Q: Is Xtram safe to use if I have a pre-existing heart condition?

The medicine's safety profile lists Orthostatic hypotension (a drop in blood pressure when standing up) as an uncommon side effect. Regulatory documents indicate that caution and special consideration may be necessary for individuals with pre-existing conditions that could be affected by cardiovascular side effects.

Q: Can older adults use Xtram?

Xtram is approved for use in adults, but for individuals aged 75 years and older, official guidelines recommend special consideration. This is because the rate at which the body eliminates the drug can be delayed, which is the basis for required adjustments to the dosing interval or maximum daily amount.

Q: Is Xtram safe for children?

Xtram is absolutely contraindicated (must not be used) in children younger than 12 years of age. Use is also officially restricted in adolescents under 18 years of age following certain types of surgery, such as tonsillectomy and/or adenoidectomy.

Q: Can Xtram affect my ability to drive or operate machinery?

Official documents caution that the medicine can cause side effects like drowsiness and dizziness. These effects may impair a person's mental and physical ability to safely perform tasks that require focus, such as driving or operating heavy machinery.

Q: Is there any risk of becoming dependent on Xtram?

Regulatory documents officially note the potential for developing physical dependence and addiction with the use of Xtram. This risk tends to increase when the medicine is used at higher doses or for a longer duration.

Q: Are there any long-term effects of taking Xtram that I should know about?

Official guidelines state that for long-term pain treatment, the ongoing need for Xtram is intended to be assessed at regular intervals. This is the regulatory framework for managing the use and documented risks associated with long-term therapy.

Q: Why are there warnings about certain activities while taking Xtram?

Warnings are generally in place because the medicine can increase the risk of serious adverse events when combined with certain substances or activities. These serious risks include respiratory depression (slow or shallow breathing), serotonin syndrome, and profound sedation.

Q: If I miss a dose of Xtram, what is the general guidance?

Official guidance for immediate-release forms is to take the dose as needed for pain. Doses should respect the minimum time interval required between administrations, and taking a double dose is not consistent with the regulatory administration instructions.

Q: Is Xtram safe for women who might become pregnant?

Use of Xtram during pregnancy is generally not recommended by regulatory agencies. This is due to the potential risk of a condition called Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn infant.

Q: Can I drink alcohol while taking Xtram?

No. Co-administration of Xtram with alcohol is formally listed as a contraindication (a situation in which the drug should not be used). Combining these substances increases the documented risk of profound sedation, severe respiratory depression, coma, and death.

Q: Does Xtram lose its effectiveness over time?

Regulatory documents indicate that repeated use of Xtram may lead to the development of tolerance. Tolerance means that over time, a person may require a higher dose of the medicine to achieve the same level of effect.

Q: Is it normal to feel a bit nauseous when starting Xtram?

Nausea is classified as a very common adverse effect of Xtram in official documents. Safety statements specifically note that common side effects like nausea and dizziness are often more frequent during the initial phase of treatment.

Q: Is it common to have vivid dreams while taking Xtram?

While vivid dreams are not typically listed as a common effect, official regulatory documents list adverse reactions, and abnormal dreams or hallucinations are sometimes included in the less common or rare categories.

Q: Can Xtram affect my blood pressure?

Official safety information lists Orthostatic hypotension as an uncommon adverse reaction. This describes a drop in blood pressure that occurs when an individual stands up from a seated or lying position.

Q: Are the research results on Xtram all positive?

Clinical trials are mandated by regulatory agencies to evaluate both the benefits (efficacy) and the documented risks (adverse events) of a medicine. Official documents summarize the findings on both efficacy and safety from these studies, aligning with the regulatory mandate to provide a comprehensive profile of the drug.

Q: Is Xtram known to cause issues with libido?

Official regulatory documents typically include a broad range of possible adverse reactions affecting different body systems. Changes in libido (sex drive) or other sexual dysfunctions may be included in the less common or rare adverse reaction categories listed in official safety documents.

Q: What if I take too much Xtram by accident?

Accidental ingestion of the medicine, particularly in children, is identified in regulatory warnings as a high risk that can result in a fatal overdose. Official safety labels include serious warnings regarding the immediate risk of life-threatening respiratory depression and overdose.

Q: Does Xtram have an immediate effect, or does it build up in the system?

The drug is rapidly absorbed, and the immediate-release form begins working quickly, generally within one hour. However, studies indicate that the body utilizes the medicine more effectively after a period of regular use, once a steady state in the bloodstream is reached.

Q: Why do official documents advise caution with Xtram for certain groups?

Cautions and warnings are established for groups who may have altered drug clearance, such as those with severe kidney or liver impairment, or those at an increased risk of severe adverse events. These measures are defined by regulators to mitigate the risks of serious effects like seizures, serotonin syndrome, and respiratory depression.

Q: Can Xtram make certain symptoms feel worse initially?

Official safety data indicates that common side effects, such as dizziness and nausea, are often more pronounced during the initial start of treatment or when the dose is first increased. These temporary effects may be perceived as a worsening, but often subside with continued use.

Q: Does Xtram have any known interaction with grapefruit?

Grapefruit and grapefruit juice are not consistently listed as formal, clinically significant food interactions in core regulatory documents for Xtram. Specific food interactions are only required to be listed when they are documented to cause a major clinical change.

Q: Is Xtram a controlled substance?

Yes, in the United States, Xtram (Tramadol) is officially classified as a Schedule IV controlled substance. This classification is due to the potential for abuse, misuse, and physical dependence.

Q: Do I need to take Xtram with food, or does it matter?

According to the official administration instructions for the immediate-release oral formulations, the medicine can be taken with or without food. Regulatory data indicates that taking it with food does not significantly change how quickly or how much of the medicine is absorbed.

How should Xtram be stored and disposed of?

How to Store and Dispose of Xtram (Tramadol Hydrochloride)

Storage Requirement Official Regulatory Mandate
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F) [Source: FDA, NIH]. Brief excursions are permitted to 15 C to 30 C (59 F to 86 F).
Protection & Container Protection from moisture and excessive heat is required for stability [Source: NIH]. Keep the medicine in its original container and keep the container tightly closed [Source: FDA, NIH].
Child Safety Due to the risk of accidental exposure to this opioid product, the medication must be stored out of the sight and reach of children [Source: EMA].
Disposal Instructions Unused or expired Xtram must be disposed of through a drug take-back program or DEA-authorized mail-back program [Source: DEA, FDA]. If no program is available, the FDA advises mixing the product with an undesirable substance before discarding it in the household trash.

These storage conditions are necessary to maintain product stability and integrity, while the mandatory disposal procedures are required for this controlled substance to mitigate the risks associated with improper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Xtram found in:

A-Z Index: